Changlee S Pang1, Mark J Pettenati2, Timothy S Pardee3. 1. Department of Pathology, Wake Forest University School of Medicine, Medical Center Boulevard, Winston Salem, North Carolina, USA. 2. Department of Genetics, Wake Forest University School of Medicine, Medical Center Boulevard, Winston Salem, North Carolina, USA. 3. Department of Hematology/Oncology, Wake Forest University School of Medicine, Medical Center Boulevard, Winston Salem, North Carolina, USA.
Abstract
AIMS: Near-tetraploidy/tetraploidy (NT/T) is a rare cytogenetic alteration in acute myeloid leukaemia (AML). NT/T-AML is categorised as complex cytogenetics and therefore, presumed to have an unfavourable prognosis. Our aim is to further characterise the clinical, morphological, cytogenetic and prognostic features of NT/T-AML. METHODS: We searched our cytogenetic laboratory database from 1991 to 2012 to reveal 13 cases of NT/T-AML. Each case was evaluated with regard to its demographics, morphology, immunophenotype and prognosis. Specific morphological features included blast size, irregularity of nuclear contours, cytoplasmic vacuoles, and presence and lineage of dysplasia. RESULTS: Eleven men and two women had a median age of 68 years. Blasts were predominately large (11/13). Eight of 13 patients had AML with myelodysplasia-related changes. Sixty-nine per cent of patients achieved complete remission (CR). Median overall survival (OS) was 8.6 months. CR rate and median OS in cases with ≥ 5 cytogenetic abnormalities were 71% and 6 months, compared with 67% and 18.1 months in cases with <5 abnormalities. CONCLUSIONS: NT/T-AML occurs in older males, exhibits large blast size and is associated with myelodysplasia. Unlike previously reported data, our study reveals an overall better prognosis in this older population with NT/T-AML than was expected for a complex karyotype AML. Cytogenetic complexity independent of ploidy status did not greatly affect the high CR rates, but did appear to be a better estimation of prognostic risk in terms of median OS. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
AIMS: Near-tetraploidy/tetraploidy (NT/T) is a rare cytogenetic alteration in acute myeloid leukaemia (AML). NT/T-AML is categorised as complex cytogenetics and therefore, presumed to have an unfavourable prognosis. Our aim is to further characterise the clinical, morphological, cytogenetic and prognostic features of NT/T-AML. METHODS: We searched our cytogenetic laboratory database from 1991 to 2012 to reveal 13 cases of NT/T-AML. Each case was evaluated with regard to its demographics, morphology, immunophenotype and prognosis. Specific morphological features included blast size, irregularity of nuclear contours, cytoplasmic vacuoles, and presence and lineage of dysplasia. RESULTS: Eleven men and two women had a median age of 68 years. Blasts were predominately large (11/13). Eight of 13 patients had AML with myelodysplasia-related changes. Sixty-nine per cent of patients achieved complete remission (CR). Median overall survival (OS) was 8.6 months. CR rate and median OS in cases with ≥ 5 cytogenetic abnormalities were 71% and 6 months, compared with 67% and 18.1 months in cases with <5 abnormalities. CONCLUSIONS:NT/T-AML occurs in older males, exhibits large blast size and is associated with myelodysplasia. Unlike previously reported data, our study reveals an overall better prognosis in this older population with NT/T-AML than was expected for a complex karyotype AML. Cytogenetic complexity independent of ploidy status did not greatly affect the high CR rates, but did appear to be a better estimation of prognostic risk in terms of median OS. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Authors: M-C Béné; G Castoldi; A Derolf; R Garand; T Haas; T Haferlach; W Knapp; E Kuhlein; P Lemez; W-D Ludwig; I Marinov; E Matutes; K Michalová; A Porwit-MacDonald; A Orfao; C Schoch; P Talmant; M B Van't Veer; Z Zemanová; M Zühlsdorf Journal: Leukemia Date: 2006-04 Impact factor: 11.528
Authors: Petr Lemež; Hana Klamová; Zuzana Zemanová; Iuri Marinov; Ota Fuchs; Jiří Schwarz; Jana Březinová; Dana Provazníková; Arnošt Kostečka; Jana Marková; Kyra Michalová; Jaroslav Jelínek Journal: Acta Haematol Date: 2011-06-24 Impact factor: 2.195
Authors: Stefan Fröhling; Richard F Schlenk; Sabine Kayser; Martina Morhardt; Axel Benner; Konstanze Döhner; Hartmut Döhner Journal: Blood Date: 2006-07-13 Impact factor: 22.113
Authors: Bruce D Cheson; John M Bennett; Kenneth J Kopecky; Thomas Büchner; Cheryl L Willman; Elihu H Estey; Charles A Schiffer; Hartmut Doehner; Martin S Tallman; T Andrew Lister; Francesco Lo-Coco; Roel Willemze; Andrea Biondi; Wolfgang Hiddemann; Richard A Larson; Bob Löwenberg; Miguel A Sanz; David R Head; Ryuzo Ohno; Clara D Bloomfield; Francesco LoCocco Journal: J Clin Oncol Date: 2003-12-15 Impact factor: 44.544
Authors: Fernanda Borges da Silva; João Agostinho Machado-Neto; Luisa Corrêa de Araujo Koury; Virginia Helena Leira Lipoli Bertini; Cristina Alonso Ratis; Maria de Lourdes Lopes Ferrari Chauffaille; Elvira Deolinda Rodrigues Pereira Velloso; Belinda Pinto Simões; Eduardo Magalhães Rego; Fabiola Traina Journal: Rev Bras Hematol Hemoter Date: 2017-08-03